Royalty Pharma's Earnings: A Preview
Benzinga Insights 8 months ago
Earnings
Royalty Pharma (NASDAQ:RPRX) is preparing to release its quarterly earnings on Wednesday, 2026-02-11. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Royalty Pharma to report an earnings per share (EPS) of $1.33.
Anticipation surrounds Royalty Pharma's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
Historical Earnings Performance
During the last quarter, the company reported an EPS beat by $0.10, leading to a 0.89% increase in the share price on the subsequent day.
Here's a look at Royalty Pharma's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 1.07 | 1.05 | 0.950 | 1.05 |
| EPS Actual | 1.17 | 1.14 | 1.057 | 1.16 |
| Price Change % | 1.00 | 0.00 | 0.000 | 0.00 |
Royalty Pharma Share Price Analysis
Shares of Royalty Pharma were trading at $44.05 as of February 09. Over the last 52-week period, shares are up 36.36%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Analyst Views on Royalty Pharma
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Royalty Pharma.
Analysts have provided Royalty Pharma with 2 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $47.5, suggesting a potential 7.83% upside.
Peer Ratings Comparison
The below comparison of the analyst ratings and average 1-year price targets of Elanco Animal Health, Jazz Pharmaceuticals and Axsome Therapeutics, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
- Analysts currently favor an Outperform trajectory for Elanco Animal Health, with an average 1-year price target of $27.25, suggesting a potential 38.14% downside.
- Analysts currently favor an Outperform trajectory for Jazz Pharmaceuticals, with an average 1-year price target of $218.0, suggesting a potential 394.89% upside.
- Analysts currently favor an Buy trajectory for Axsome Therapeutics, with an average 1-year price target of $216.6, suggesting a potential 391.71% upside.
Snapshot: Peer Analysis
The peer analysis summary provides a snapshot of key metrics for Elanco Animal Health, Jazz Pharmaceuticals and Axsome Therapeutics, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| Viatris | Buy | 0.23% | $1.37B | -0.83% |
| Elanco Animal Health | Outperform | 10.39% | $607M | -0.50% |
| Jazz Pharmaceuticals | Outperform | 6.74% | $997.23M | 6.56% |
| Axsome Therapeutics | Buy | 63.22% | $159.08M | -64.34% |
Key Takeaway:
Royalty Pharma ranks at the bottom for Revenue Growth and Gross Profit among its peers. It is in the middle for Return on Equity.
Discovering Royalty Pharma: A Closer Look
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Key Indicators: Royalty Pharma's Financial Health
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Royalty Pharma displayed positive results in 3 months. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 7.9%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Royalty Pharma's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 47.3% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Royalty Pharma's ROE excels beyond industry benchmarks, reaching 4.52%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Royalty Pharma's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.53%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 1.39, Royalty Pharma faces challenges in effectively managing its debt levels, indicating potential financial strain.
To track all earnings releases for Royalty Pharma visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.